Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
ROCKVILLE, Md., Feb. 25, 2016 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the Cowen & Company 36th Annual Health Care Conference.
Date: Monday, March 7, 2016
Time: 2:40 p.m. ET
Place: The Boston Marriott Copley Place, Boston, MA
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD. SPN-812 is being developed for treatment of ADHD.
CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 Or Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
